Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus
physician's choice as maintenance therapy for patients with advanced breast cancer who
achieved disease control after salvage treatment.